Skip to main content

Study of DF1001 in Patients With Advanced Solid Tumors

Trial Status: Active

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having either selected solid tumors, or solid tumors expressing high levels of HER2. A combination therapy cohort of DF1001 and pembrolizumab will also be opened for enrollment.

Inclusion Criteria

  • Inclusion Criteria: General (applies to all cohorts) 1. Signed written informed consent. 2. Male or female patients aged ≥ 18 years. 3. Histologically or cytologically proven locally advanced or metastatic solid tumors. Primary tumor must have documented HER2 expression by immunohistochemistry. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at study entry and an estimated life expectancy of at least 3 months. 5. Baseline Left Ventricular Ejection Fraction (LVEF) ≥ 55% measured by echocardiography (preferred) or multigated acquisition (MUGA) scan. 6. Adequate hematological function. 7. Adequate hepatic function. 8. Adequate renal function. 9. Effective contraception for women of child bearing potential (WOCBP) patients as defined by World Health Organization (WHO) guidelines for 1 "highly effective" method or 2 "effective" methods. Inclusion Criteria: Dose Escalation 1. Evidence of objective disease, but participation does not require a measurable lesion. 2. Archived tumor biopsy available Inclusion Criteria: Safety/PK/PD Expansion Cohorts 1. Fresh tumor biopsy must be obtained during the screening window 2. HER2 by immunohistochemistry (IHC) Inclusion Criteria: Urothelial Bladder Cancer Expansion Cohort 1. Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary urothelial, urethra). 2. Patients must have radiographic disease progression after their last line of therapy. 3. Patients must have received one (and no more than one) platinum-containing regimen (eg, platinum plus another agent such as gemcitabine, methotrexate, vinblastine, doxorubicin, etc.) for inoperable locally advanced or metastatic urothelial carcinoma with radiographic progression or with recurrent disease 4. Patients must have received treatment with a checkpoint inhibitor (CPI) (i.e., anti-PD-1 or anti-PD-L1), with radiographic progression. 5. Patients must have expression of HER2 by IHC. 6. A fresh tumor biopsy must be obtained during the screening window Inclusion Criteria: Metastatic Breast Cancer (MBC) Expansion Cohort 1. Patients must have histologically confirmed MBC. 2. Patients must have received no more than 3 prior lines of cytotoxic therapy for metastatic disease. 3. Patients must have received a taxane and an anthracycline unless anthracycline is contraindicated. 4. Patients must have HER2 expression by IHC 5. Patients must have progressed (radiographically) after their last line of systemic therapy. 6. A fresh tumor biopsy must be obtained during the screening window Inclusion Criteria: HER-2 High Basket Cohort 1. Patients with any solid tumor except breast cancer or gastric cancer HER2 high expression by IHC 2. Patients must have received at least one prior line of an approved or established therapy. 3. A fresh tumor biopsy must be obtained during the screening window Inclusion Criteria: Combination Therapy with Pembrolizumab 1. Patients must be eligible to receive pembrolizumab per its label for a malignancy of epithelial origin. 2. A fresh tumor biopsy must be obtained during the screening window Exclusion Criteria: 1. Concurrent treatment with a non-permitted drug as in Non-Permitted Medicines and Therapies section. Previous treatment with drugs that specifically target the HER2 pathway (mAb or tyrosine kinase inhibitor [TKI]) is acceptable providing washout period (4 weeks for mAbs or protein therapeutics and 2 weeks for a TKI). 2. Concurrent anticancer treatment (eg, cytoreductive therapy, radiotherapy [with the exception of palliative bone directed radiotherapy], immune therapy, or cytokine therapy except for erythropoietin), major surgery (excluding prior diagnostic biopsy), concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 28 days before the start of study treatment. Short-term administration of systemic steroids (i.e., for allergic reactions or the management of immune-related adverse events [irAEs]) is allowed. Note: Patients receiving bisphosphonates are eligible provided treatment was initiated at least 14 days before the first dose of DF1001. 3. Previous malignant disease other than the target malignancy to be investigated in this study within the last 3 years, with the exception of basal or squamous cell carcinoma of the skin or cervical carcinoma in situ. 4. Rapidly progressive disease. 5. Active or history of central nervous system (CNS) metastases. 6. Receipt of any organ transplantation including autologous or allogeneic stem-cell transplantation. 7. Significant acute or chronic infections (including historic positive test for human immunodeficiency virus [HIV], or active or latent hepatitis B or active hepatitis C tested during the screening window). 8. Preexisting autoimmune disease (except for patients with vitiligo) needing treatment with systemic immunosuppressive agents for more than 28 days within the last 3 years or clinically relevant immunodeficiencies (eg, dys-gammaglobulinemia or congenital immunodeficiencies), or fever within 7 days of Day 1. 9. Known severe hypersensitivity reactions to mAbs (≥ Grade 3 NCI-CTCAE v5.0), any history of anaphylaxis, or uncontrolled asthma (ie, 3 or more features of partly controlled asthma). 10. Persisting toxicity related to prior therapy > Grade 1 NCI-CTCAE v5.0, however alopecia and sensory neuropathy ≤ Grade 2 is acceptable. 11. Pregnancy or lactation in females during the study. 12. Known alcohol or drug abuse. 13. Serious cardiac illness 14. All other significant diseases (e.g., inflammatory bowel disease), which, in the opinion of the Investigator, might impair the patient's ability to participate 15. Any psychiatric condition that would prohibit the understanding or rendering of informed consent. 16. Legal incapacity or limited legal capacity. 17. Incapable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

New York

New York
Icahn School of Medicine at Mount Sinai
Status: ACTIVE

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: APPROVED

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE
Contact: Vivek Subbiah
Phone: 713-563-1930

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Dragonfly Therapeutics

  • Primary ID DF1001-001
  • Secondary IDs NCI-2020-03830
  • Clinicaltrials.gov ID NCT04143711